Clinical Genomics purchase
October 9, 2013
Australian biotech firm
Clinical Genomics has announced
the acquisition of US-based cancer
screening company Enterix Inc.
The deal, which includes Enterix’
Sydney subsidiary, gives Clinical
Genomics a regulatory licensed
manufacturing facility in both the
US and Australia, as well as access
to a specialty pathology operation
in Australia for selling bowel cancer
screening services.
The company said it plans to use
the acquisition as the platform for
the launch of a new blood test for
colorectal cancer in early 2014.
The purchase also gives
Clinical Genomics ownership
of the patented InSure fecal
immunochemical test (FIT) “brush
test” product line currently used by
the BowelScreen Australia Program,
which will be combined with the
new blood plasma test to deliver a
comprehensive colorectal cancer
screening portfolio.
CEO Lawrence LaPointe said
the acquisition was an exciting
milestone, marking a “key step
in our transition from a biotech
company focused primarily on
research and development into a
commercial entity with a portfolio
of cancer screening products and
an exciting pipeline”.
Bowel Cancer Australia ceo Julien
Wiggins hailed the move, saying
it was exciting that Australia will
now be the country that launches a
blood test for bowel cancer.
“With this decision we have a real
opportunity to be a world leader,”
Wiggins said.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Oct 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Oct 13
